Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Premier’s mission is “to improve the health of communities” and using the power of collaboration to lead the transformation to high-quality, cost-effective care aligns with Meridian’s promise to provide a new standard for patient care with our innovative diagnostic testing solutions such as the illumigene molecular system. The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology, an efficient system which allows Meridian to provide customers the illumipro–10™ instrument without a capital investment or costly annual service contract. The illumigene procedure is simple, highly sensitive, and yields results in less than one hour, which helps drive improvements in the early diagnosis and treatment of preventable diseases.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Meridian Bioscience Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700